2015
Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)
Powles T, Nickles D, Van Allen E, Chappey C, Zou W, Kowanetz M, Kadel E, Denker M, Boyd Z, Vogelzang N, Kim J, Bellmunt J, Loriot Y, Drake C, O'Hear C, Fasso M, Hegde P, Mariathasan S. Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC). Journal For ImmunoTherapy Of Cancer 2015, 3: p83. PMCID: PMC4645499, DOI: 10.1186/2051-1426-3-s2-p83.Peer-Reviewed Original Research
2012
Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response
Kim JW, Bilusic M, Heery CJ, Madan RA. Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response. Cancers 2012, 4: 1229-1246. PMID: 24213505, PMCID: PMC3712729, DOI: 10.3390/cancers4041229.Peer-Reviewed Original ResearchClinical benefitIntermediate markersImmunotherapy clinical trialsTherapeutic cancer vaccinesPotential clinical roleTumor growth kineticsOverall survivalImmune infiltratesClinical outcomesCytokine responsesCancer vaccinesCellular immunityIntermediate biomarkersPeripheral bloodCancer immunotherapyClinical trialsParadoxical patternProstate cancerClinical roleProspective assessmentSystemic responseTherapy mechanismsBiomarkersImmunotherapySurvival